A Phase II Study With Low-dose Recombinant Human IL-2 for the Treatment of Primary Sjögren's Syndrome

NCT02464319 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Primary Sjögren's Syndrome

Interventions

DRUG: hrIL-2 active
DRUG: hrIL-2 placebo

Sponsor

Peking University People's Hospital

Collaborators

[object Object]
[object Object]